Navigation Links
REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
Date:6/1/2009

by the combination treatment. In addition, the combination of RGI-2001 with low-dose Sirolimus significantly enhanced Treg induction.

The results indicate the potential of RGI-2001 to be a key component of a novel tolerance induction regimen, avoiding the use of calcineurin inhibitors that are not only associated with high toxicity but suppress Treg activity. The finding suggests the possibility to develop a pharmacological approach to induce long-term transplant tolerance by promoting the body's intrinsic tolerogenic pathways using RGI-2001.

RGI-2001 is in late preclinical development and REGiMMUNE plans to file an Investigational New Drug (IND) for the prevention of acute GvHD associated with bone marrow transplantation later this year.

The poster presentation is scheduled during the session "Tolerance I: Regulatory Cells" today in Exhibit Hall C, Hynes Convention Center. It is available for viewing from 8:00 am to 6:30 pm; and the authors, Drs. Omar Duramad and Reiko Namikawa, will be present from 5:30 pm to 6:30 pm for discussion and questions.


'/>"/>

Contact: Debra Bannister
530-676-8001
REGiMMUNE
Source:Eurekalert

Page: 1 2

Related biology news :

1. REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs
2. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
3. GSA special paper presents new studies of Western US earth motion
4. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
5. AIUM presents 2009 Memorial Hall of Fame awards
6. AIUM presents 2009 Distinguished Sonographer award
7. AIUM presents 2009 William J. Fry Memorial Lecture award
8. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
9. Understanding soil carbon sequestration: New book presents key concepts
10. World Congress on Osteoporosis 2010 presents outstanding scientific program
11. New manual presents robust, state-of-the-art proteomics methods for teaching and research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... Chip" developed at the University of Colorado at Boulder ... strains from patient samples within hours may help world ... last month on the new technology by the Centers ... CU-Boulder Flu Chip can determine the genetic make-up of ...
... old, in fact, which comes as a surprise to a ... the world's largest tropical region. , Using radiocarbon dating methods, ... up to half of all trees greater than 10 centimeters ... the trees, Trumbore said, are as much as 750 to ...
... (NCI) and the National Human Genome Research Institute ... Health (NIH), today launched a comprehensive effort to ... cancer through the application of genome analysis technologies, ... The Cancer Genome Atlas (TCGA), will begin with ...
Cached Biology News:New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 2New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 3New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 4Amazon trees much older than assumed, raising questions on global climate impact of region 2NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... Patients , Study will provide new insights on mechanics of fecal microbiota transplantation ... new partnership to study the microbiome of patients undergoing fecal microbiota transplantation (FMT) ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... at the Swedish medical university Karolinska Institutet shows that ... LDL cholesterol and thereby cause an inflammation that leads ... cell receptors, the researchers have managed to inhibit the ... online in the distinguished periodical Journal of Experimental ...
... Concludes restatement of prior financial results , , ... call at 4:30 EDT today , , ... May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) (the "Company") today ... Company also announced today that it filed its Annual Report on Form 10-K for the ...
... The Netherlands , May 6, 2010 ... CRXL ; Swiss,Exchange: CRX) today announced the award from ... its paediatric vaccine Quinvaxem(R) to the developing,world. Paediatric vaccination ... Development Goals set by the United Nations, in,particular the ...
Cached Biology Technology:New atherosclerosis vaccine gives promising results 2Oncothyreon reports full year and fourth quarter 2009 financial results 2Oncothyreon reports full year and fourth quarter 2009 financial results 3Oncothyreon reports full year and fourth quarter 2009 financial results 4Oncothyreon reports full year and fourth quarter 2009 financial results 5Oncothyreon reports full year and fourth quarter 2009 financial results 6Oncothyreon reports full year and fourth quarter 2009 financial results 7Oncothyreon reports full year and fourth quarter 2009 financial results 8Oncothyreon reports full year and fourth quarter 2009 financial results 9Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 2Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 3Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 4
... White crystalline solid. PACKAGED UNDER ... Contaminants: DNases, proteases, RNases: none ... nm): ≤0.500; (100 mM, 1 cm, 280 ... Soluble in H 2 O. RTECS ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... Salmonella genomes has allowed the development of ... pairs. The S. enterica Typhimurium (strain LT2) ... bp; 4,440 ORFs) and a plasmid, pSLT ... Sigma-Genosys have been designed to amplify all ...
... productivity and allows you to achieve a higher ... beyond traditional paper-based weighing processes into a powerful ... Control of ... PR, SR, PG-S, PG, SG, AT, MT, UMT, ...
Biology Products: